BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
10.59
+0.20 (1.92%)
May 23, 2025, 4:00 PM - Market closed
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for BioCryst Pharmaceuticals stock ranges from a low of $11 to a high of $30. The average analyst price target of $16.75 forecasts a 58.17% increase in the stock price over the next year.
Price Target: $16.75 (+58.17%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 3 | 3 | 3 | 4 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold Maintains $8 → $11 | Hold | Maintains | $8 → $11 | +3.87% | May 7, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $11 → $13 | Buy | Reiterates | $11 → $13 | +22.76% | May 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $10 → $13 | Buy | Maintains | $10 → $13 | +22.76% | May 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +183.29% | May 6, 2025 |
| Needham | Needham | Strong Buy Maintains $15 → $17 | Strong Buy | Maintains | $15 → $17 | +60.53% | May 6, 2025 |
Financial Forecast
Revenue This Year
615.74M
from 450.71M
Increased by 36.61%
Revenue Next Year
696.95M
from 615.74M
Increased by 13.19%
EPS This Year
0.03
from -0.43
EPS Next Year
0.38
from 0.03
Increased by 1,136.66%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 649.7M | 770.8M | 881.5M | ||
| Avg | 615.7M | 697.0M | 787.7M | ||
| Low | 552.7M | 591.9M | 693.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.2% | 25.2% | 26.5% | ||
| Avg | 36.6% | 13.2% | 13.0% | ||
| Low | 22.6% | -3.9% | -0.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.37 | 0.89 | 1.58 | ||
| Avg | 0.03 | 0.38 | 0.85 | ||
| Low | -0.26 | 0.04 | 0.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,784.9% | 311.7% | ||
| Avg | - | 1,136.7% | 121.2% | ||
| Low | - | 26.7% | -5.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.